Poly Medicure Limited has informed the Exchange regarding Appointment of Mr. Pankaj Kumar Gupta as Additional Director (Executive Director) of the company w.e.f. August 08, 2025.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Smallcap 250 and 1.0 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Poly Medicure's board, at its August 8, 2025 meeting, approved Q1 FY26 results showing strong growth. Standalone revenue from operations rose to Rs 38,404.67 lakhs (vs Rs 36,742.47 lakhs in Q1 FY25) and standalone profit after tax jumped to Rs 8,792.89 lakhs (vs Rs 7,230.25 lakhs), a growth of about 22%. On a consolidated basis, PAT grew to Rs 9,308.29 lakhs (vs Rs 7,403.94 lakhs), with EPS of Rs 9.19 vs Rs 7.71. The board appointed Mr. Pankaj Kumar Gupta, the company's President of Operations for over 17 years, as Executive Director for five years. Two Independent Directors, Mr. Amit Khosla and Ms. Sonal Mattoo, were re-appointed for another five-year term. The board also granted 3,400 stock options under ESOP 2020 at Rs 100 per share and re-appointed M/s Jai Prakash & Company as Cost Auditors for FY25-26.
Strong double-digit profit growth in Q1 FY26 signals healthy business momentum and is positive for shareholders. The internal elevation of an experienced operations leader to the board reinforces management continuity, while the ESOP grant and re-appointments are routine governance items.